Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

A collaborative effort by the Formosa-Jordan lab from the Max Planck Institute for Plant Breeding Research in Cologne, ...

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...

Scientists discovered ribose — in addition to “all five nucleobases used to construct both DNA and RNA” — on asteroid Bennu, ...

Colibactin is a powerful toxin produced by Escherichia coli and other bacteria living in the human gut. This highly unstable ...

The approval was supported by data from phase 3 STEER study, which enrolled patients with SMA who were treatment-naive and able to sit but never able to walk independently.

Inside the station, every surface was wrapped with more ads—babies on turnstiles, on staircases, on banners overhead. “Think ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new ...

A closeup look at colibactin’s structure reveals chemical motifs that guide its mutation-wreaking “warheads” to specific stretches of DNA.

The global liquid biopsy market, poised for significant growth, benefits from increased demand for non-invasive cancer ...